DirectorsTalk Interviews focus on financial markets and investment opportunities. The site features interviews with company directors, market analysts, and experts, offering insights into companies' performance, industry trends, and market updates.
The content includes Q&A sessions, market commentary, and discussions about business developments, often highlighting the viewpoints of executives from publicly traded companies.
Meridian Holdings Profits Rise, Debt Falls 65% and the Focus Shifts to Sustained Growth
Meridian Holdings (NASDAQ: MRDN) is sharpening its focus on profitability after delivering a second consecutive profitable quarter, a 43% rise in adjusted EBITDA and a 65% reduction in net debt. Chairman and CFO William Scott explains how the gaming group is strengthening its balance sheet, extending debt maturities to 2031 and using its proprietary technology to support expansion. He also addresses the impact of regulatory developments in Brazil, the role of acquisitions and why consistent cash generation could prove crucial to Meridian's next stage of growth.
Key Moments
00:00 Meridian’s transformation and leadership changes
00:51 Two profitable quarters and EBITDA up 43%
01:18 Inside Meridian’s diversified gaming businesses
02:55 Why owning the technology matters
03:35 700 betting shops and a regulated market presence
04:01 Net debt down 65% and repayment terms extended
04:57 Brazil’s regulatory shake-up and Meridian’s exposure
06:26 Customer growth, technology and disciplined acquisitions
07:27 Putting Meridian on investors’ radars
08:24 The message to retail shareholders
08:57 What investors should watch over the next 12 months
8 Oct 2026
Genflow Biosciences: SLAB-VET Results Put SIRT6 Partnering and Human Therapies in Focus
Genflow Biosciences (LON:GENF / OTCQB:GENFF) has reported encouraging interim results from its SLAB-VET-001 study, giving investors an early look at how its centenarian-derived SIRT6c gene therapy performs in naturally aged dogs. CEO Dr Eric Leire explains why the findings matter, why plasmid DNA has emerged as the preferred veterinary delivery route, how the data are accelerating discussions with animal health companies and why progress in dogs could have wider implications for Genflow’s human sarcopenia programme.
Key Moments
00:09 – SLAB-VET delivers an important milestone
Dr Leire explains why testing SIRT6c in naturally aged dogs marks a significant step.
00:44 – A centenarian-derived gene moves into real-world ageing
Early signs from older animals provide a new test of Genflow’s longevity approach.
01:05 – Why pDNA is leading the veterinary programme
Lower manufacturing costs, scalability and a potentially simpler safety profile underpin the choice.
01:39 – Repeat dosing could strengthen the commercial case
Dr Leire highlights practical advantages over viral-vector delivery.
02:11 – Toronto data draw industry attention
Scientists, delegates and animal health companies focus on changes in biological age and muscle performance.
02:37 – Naturally aged dogs add translational relevance
The study differs from laboratory models engineered to accelerate ageing.
03:11 – Results accelerate licensing discussions
Genflow says the presentation has strengthened engagement with potential commercial partners.
03:33 – Partnering rather than building an animal-health business
The company is targeting licensing, milestone and royalty structures or a potential outright asset sale.
04:19 – Three catalysts investors should watch
Veterinary partnering, patent progress and advancement of the human programmes take centre stage.
04:25 – A veterinary deal could bring non-dilutive value
Management sees partnering as a potential source of capital and external validation for the platform.
04:44 – Europe and Japan patent progress
Genflow expects further intellectual-property milestones around its SIRT6 technology.
05:04 – Sarcopenia moves higher up the agenda
Positive dog data increase the relevance of Genflow’s work targeting age-related muscle decline in humans.
05:30 – Why dogs may matter more than mice
Shared environments and lifestyles could make naturally aged dogs a more relevant translational model.
05:50 – Eye and liver programmes add further optionality
Genflow continues to advance additional therapeutic opportunities beyond sarcopenia.
Oriole Resources CEO Martin Rosser explains why the 32.2Mt maiden resource at Wapouzé could support a multi-decade operation — and potentially generate income to help fund ORR’s gold strategy while limiting dilution.
Also covered: partner discussions, licensing, Mbe, Bibemi, Eastern CLP and Senala.
#ORR #Gold #Mining #Cameroon
Key Moments
00:13 – Wapouzé delivers a 32.2Mt maiden resource
Martin puts the scale and quality of the new resource into context.
00:50 – High-grade material with multi-decade potential
Why the calcium oxide grade, low magnesium content and proposed 400,000tpa operation matter.
01:30 – A route into Cameroon’s cement market
The potential to displace imported clinker and supply domestic cement production.
02:06 – More than a cement opportunity
Higher-grade material could also serve gold processing and chemical-grade markets.
02:39 – Location strengthens the commercial case
Wapouzé’s position offers potential access to customers in both Cameroon and neighbouring Chad.
03:22 – Moving from resource towards reserves
The technical, economic and mining work now required to advance the project.
03:50 – Exploitation licence work gathers pace
The PEA and environmental and social impact assessment form key parts of the application.
04:38 – Industry partner discussions move forward
Oriole is targeting established domestic players and international groups seeking exposure to the Cameroon and Chad markets.
05:44 – The resource strengthens Oriole’s negotiating position
The maiden MRE provides substantially more technical information to advance partner discussions.
06:27 – A potentially faster route to production
Martin explains why quarry development could require less capital and move more quickly than a conventional metals mine.
07:17 – Wapouzé could help fund the gold strategy
Oriole sees potential for royalty-based or other income that could support exploration while reducing dilution.
08:02 – Oriole’s portfolio takes shape
Martin reviews the 1.66Moz Mbe resource, 460,000oz at Bibemi, Wapouzé and Senala.
08:34 – From exploration towards development
The company is increasingly focused on defining routes to development and eventual gold production.
09:06 – The next portfolio catalysts
Bibemi licensing, Mbe economics, Eastern CLP exploration and results from Managem’s US$2m Senala programme are all in focus.
Host of DirectorsTalk Interviews?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
